How PD-L1 Biomarker Test Results Impact Clinical Management of Lung Cancer

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Drs. Goeffrey Oxnard and Lauren Ritterhouse review how the results of PD-L1 testing influence the choices in first- or second-line immunotherapy or combination immunochemotherapy in patients with squamous or non-squamous non-small-cell lung cancer.

Related Videos

November 3, 2014

New Data on PV Studies

Listen as Dr. Mesa discusses exciting new data in polycythemia vera on studies on hydrea coming out of ASCO and ASH.Supported through funding from Incyte

August 29, 2018

Accurate and Reproducible Measurement of PD-1/PD-L1

Drs. Geoff Oxnard and Lauren Ritterhouse discuss PD-1/PD-L1 as a routine biomarker test run on all lung cancer biopsy specimens, as well as on other selected cancer types, and how qualitative and quantitative results are typically reported.